Can Metoprolol Be Used in Diastolic Heart Failure (HFpEF)?
Metoprolol is NOT routinely recommended for heart failure with preserved ejection fraction (HFpEF) as there is no evidence it reduces mortality or hospitalizations in this population. However, it may be used when specific indications exist, such as prior myocardial infarction (within 3 years), angina, or atrial fibrillation requiring rate control 1, 2.
Key Evidence and Rationale
The distinction between heart failure with reduced ejection fraction (HFrEF) and HFpEF is critical here. The mortality benefit of metoprolol succinate is established only for HFrEF (EF ≤40%), not for HFpEF (EF ≥50%) 3, 4.
Why Metoprolol Works in HFrEF But Not HFpEF
- In HFrEF: Metoprolol succinate (sustained-release) is one of only three beta-blockers proven to reduce mortality (along with bisoprolol and carvedilol) 5, 3
- In HFpEF: Multiple trials have failed to demonstrate benefit. Beta-blockers showed no mortality reduction in HFpEF populations 1, 6, 7
- Important caveat: Short-acting metoprolol tartrate was less effective even in HFrEF trials and should not be used 3, 8
When to Consider Metoprolol in HFpEF Patients
Use metoprolol in HFpEF only when these specific indications exist 1, 2:
- Post-myocardial infarction (up to 3 years after event)
- Angina pectoris requiring symptom control
- Atrial fibrillation requiring rate control
Critical monitoring point: Watch for chronotropic incompetence and reduced exercise tolerance, as beta-blockers can worsen functional capacity in HFpEF patients who rely on heart rate augmentation during exertion 1.
Current Evidence-Based Treatment for HFpEF
Instead of metoprolol, focus on therapies with proven benefit in HFpEF 1, 2:
Class I Recommendations (Proven Benefit):
- SGLT2 inhibitors (empagliflozin or dapagliflozin): Reduce HF hospitalizations and cardiovascular mortality 1, 2
- Diuretics: For congestion management and symptom relief 4, 1
Class IIa/IIb Recommendations:
- Mineralocorticoid receptor antagonists (spironolactone): May reduce HF hospitalizations 1, 2
- ARNi (sacubitril/valsartan): Consider in select patients, particularly those with lower-range EF (45-57%) 1, 2
Research Evidence Limitations
A small pilot study 9 suggested possible benefit of metoprolol succinate in HFpEF with improvements in NYHA class and quality of life, but this was underpowered (n=40) and showed no significant changes in objective endpoints. A 2024 meta-analysis 10 of observational studies showed 19% reduction in all-cause mortality but no effect on HF rehospitalization—however, observational data cannot substitute for randomized controlled trials, and selection bias likely explains these findings.
Practical Algorithm for Beta-Blocker Use in HFpEF
Step 1: Confirm HFpEF diagnosis (EF ≥50%, elevated natriuretic peptides, structural/functional cardiac abnormalities) 4
Step 2: Assess for specific indications:
- Recent MI (<3 years)? → Yes to metoprolol
- Angina symptoms? → Yes to metoprolol
- Atrial fibrillation needing rate control? → Yes to metoprolol
- None of the above? → No metoprolol; use SGLT2i instead
Step 3: If metoprolol is indicated for secondary reasons, use metoprolol succinate (not tartrate), starting at 12.5-25 mg daily, targeting 200 mg daily 11, 12
Step 4: Monitor exercise tolerance closely—if functional capacity worsens, consider dose reduction or discontinuation 1
Common Pitfalls to Avoid
Do not extrapolate HFrEF data to HFpEF: The beta-blocker benefit is NOT a class effect and does NOT extend to preserved EF 3, 1
Do not use metoprolol tartrate: Only sustained-release metoprolol succinate showed mortality benefit in HFrEF trials 3, 8
Do not withhold proven HFpEF therapies: SGLT2 inhibitors have the strongest evidence base for HFpEF and should be first-line 1, 2
Do not ignore comorbidities: Hypertension, diabetes, obesity, and atrial fibrillation management are critical in HFpEF 1, 6